Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarlatamab - Amgen

Next Previous
Drug Profile

Tarlatamab - Amgen

Alternative Names: AMG-757; IMDELLTRA; Imdelltra; IMDYLLTRA; Imdylltra; Tarlatamab-dlle

Latest Information Update: 21 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; BeOne Medicines
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase I/II Glioma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 21 Apr 2026 Amgen initiates enrolment in the phase-Ib DeLLphi-313 trial for Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT07531095)
  • 15 Apr 2026 Amgen plans a phase Ib DeLLphi-313 trial for Small cell lung cancer (Combination therapy, Second line therapy or greater) (IV) in May 2026 (NCT07531095)
  • 26 Mar 2026 Preregistration for Small cell lung cancer (Second-line therapy or greater, Late-stage diseases) in European Union (IV) prior to April 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top